

Exhibit E

Exhibit E

BMS/OTN Price Dispersion: Excluding Sales to Federal Entities

% of Net Revenue at Net Transaction Prices

Blenoxane

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%		0.0%	0.0%	0.1%	1.3%	3.3%	32.7%	70.4%	69.2%	6.4%	0.0%	16.6%
50 - <75% of WLP	0.5%	1.2%	1.5%	5.8%	61.3%	80.2%	79.0%	57.9%	22.7%	24.5%	25.8%	2.2%	63.3%
75 - <90% of WLP	0.0%			13.8%	21.2%	8.6%	2.7%	1.1%	0.6%	0.0%	5.0%	3.2%	7.9%
90 - <95% of WLP	0.9%	0.0%	2.7%	14.3%	2.1%	0.2%					2.8%	4.3%	0.6%
>95% of WLP	98.6%	98.8%	95.9%	66.1%	15.3%	9.8%	15.0%	8.3%	6.3%	6.3%	59.9%	90.4%	11.6%

Cytosan

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	18.7%	48.9%	53.0%	66.0%	82.3%	86.1%	93.8%	78.9%	93.4%	70.8%	60.5%		60.5%
50 - <75% of WLP	14.7%	10.9%	4.8%	2.1%	1.3%	0.9%	0.2%	0.0%	-0.1%	0.0%	5.4%		5.4%
75 - <90% of WLP	1.0%	0.7%	0.7%	0.1%	0.0%	0.0%	0.0%		-0.3%		0.4%		0.4%
90 - <95% of WLP	0.3%	0.0%	0.0%	0.0%	0.0%		0.0%				0.1%		0.1%
>95% of WLP	65.4%	39.5%	41.5%	31.8%	16.4%	13.0%	6.0%	21.1%	6.9%	29.1%	33.7%		33.7%

Cytosan Tablets

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	0.0%	0.0%	0.0%		0.0%	0.0%	0.0%		0.0%	0.0%	0.0%
50 - <75% of WLP	0.2%	0.8%	0.9%	0.7%	0.0%	0.0%	0.0%	0.2%	2.1%	24.6%	1.8%	0.4%	7.2%
75 - <90% of WLP	0.0%	0.0%	0.0%	0.1%		0.1%	0.0%	0.0%		0.1%	0.0%	0.0%	0.0%
90 - <95% of WLP	0.0%	0.0%	2.1%	0.0%	0.1%	0.1%	26.8%	9.2%		0.0%	4.4%	4.7%	3.4%
>95% of WLP	99.7%	99.2%	96.9%	99.2%	99.9%	99.8%	73.1%	90.6%	97.9%	75.4%	93.8%	94.9%	89.3%

Etopophos

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP					0.0%						0.0%	0.0%	
50 - <75% of WLP											0.0%	0.0%	
75 - <90% of WLP				0.1%							0.0%	0.0%	
90 - <95% of WLP													
>95% of WLP				99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	

Paraplatin

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	0.0%		0.0%	0.0%	0.0%		0.0%	0.0%	0.0%	0.0%	
50 - <75% of WLP	0.1%	0.5%	0.6%	0.5%	0.0%	0.1%	0.1%	0.0%	0.0%	0.0%	0.1%	0.1%	
75 - <90% of WLP	0.1%	0.0%	0.0%	0.2%	0.2%	0.0%	0.0%		0.2%	11.3%	1.8%	1.8%	
90 - <95% of WLP	1.3%	0.0%	4.0%	3.4%	5.5%	1.4%	1.6%	2.0%	5.2%	5.3%	3.3%	3.3%	
>95% of WLP	98.5%	99.5%	95.3%	95.9%	94.3%	98.5%	98.3%	97.9%	94.5%	83.3%	94.7%	94.7%	

Rubex

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP		54.9%	73.3%	60.0%	57.4%	92.8%	51.6%	84.0%	37.9%	100.0%	63.2%		63.2%
50 - <75% of WLP		0.9%	0.5%								0.2%		0.2%
75 - <90% of WLP													
90 - <95% of WLP													
>95% of WLP		44.1%	26.2%	40.0%	42.6%	7.2%	48.4%	16.0%	62.1%	0.0%	36.6%		36.6%

Defendants' Exhibit

2524

01-12257 - PBS

Exhibit E

BMS/OTN Price Dispersion: Excluding Sales to Federal Entities

% of Net Revenue at Net Transaction Prices

Taxol

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%		0.0%	0.0%	0.0%		0.0%		0.0%	46.7%	1.3%	0.0%	10.0%
50 - <75% of WLP	0.0%	0.0%				0.0%			6.0%	24.4%	1.3%	0.0%	9.9%
75 - <90% of WLP	0.1%	0.2%	0.3%	0.8%	0.0%	0.1%	0.2%	0.0%	25.6%	28.3%	3.6%	0.2%	26.2%
90 - <95% of WLP	0.0%	0.0%			0.0%			4.6%	27.2%	0.1%	3.7%	1.0%	21.4%
>95% of WLP	99.8%	99.8%	99.7%	99.2%	100.0%	99.9%	99.8%	95.3%	41.2%	0.5%	90.1%	98.8%	32.5%

Vepesid

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	11.2%	72.6%	78.5%	80.1%	85.6%	45.0%	80.0%	88.9%	15.3%	0.0%	43.1%
50 - <75% of WLP	0.2%	30.9%	63.7%	7.4%	1.7%	0.4%	0.3%	0.0%	0.0%	0.1%	18.7%	10.9%	32.7%
75 - <90% of WLP	2.5%	37.8%	8.4%	1.3%	0.0%	-0.7%	-0.4%	-0.4%	-0.5%	0.1%	11.1%	14.9%	4.3%
90 - <95% of WLP	1.0%	2.1%	1.2%	0.1%	0.2%	0.3%		0.1%			1.1%	1.4%	0.6%
>95% of WLP	96.3%	29.3%	15.5%	18.5%	19.6%	19.9%	14.5%	55.3%	20.5%	11.0%	53.8%	72.8%	19.2%

Vepesid Capsules

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		0.0%		0.1%	0.0%	0.0%	0.1%
50 - <75% of WLP	0.6%	0.9%	0.8%	1.1%	0.0%	0.1%	0.1%	0.0%	0.0%	0.7%	0.4%	0.4%	0.7%
75 - <90% of WLP		0.5%	1.4%	0.6%	0.0%	0.3%	0.2%	0.1%	0.0%	0.0%	0.3%	0.3%	0.0%
90 - <95% of WLP	0.1%	0.0%	0.3%	0.8%	0.3%	0.2%	13.6%	20.7%	0.3%	7.2%	4.6%	4.5%	7.2%
>95% of WLP	99.3%	98.6%	97.5%	97.5%	99.7%	99.5%	86.1%	79.2%	99.7%	92.0%	94.6%	94.8%	92.0%

All Products

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP	0.8%	1.0%	2.1%	3.7%	1.9%	1.2%	1.0%	1.0%	1.5%	11.4%	2.2%	0.0%	19.9%
50 - <75% of WLP	0.7%	6.0%	7.0%	0.8%	1.6%	1.4%	1.4%	0.6%	3.0%	5.6%	2.4%	0.5%	17.5%
75 - <90% of WLP	0.9%	6.8%	1.1%	1.2%	0.6%	0.2%	0.1%	0.0%	12.0%	14.1%	3.2%	1.4%	17.5%
90 - <95% of WLP	0.7%	0.4%	1.3%	1.5%	1.8%	0.5%	1.2%	4.0%	15.2%	4.1%	3.4%	2.1%	13.6%
>95% of WLP	96.9%	85.8%	88.6%	92.7%	94.1%	96.7%	96.3%	94.3%	68.3%	64.8%	88.8%	96.0%	31.5%

Sources:

BMS invoice data from SHARP: DirectSales_IncludingPHS.txt
Pre1997-Direct.txt

OTN invoice data: OTN Blenoxane.txt OTN Blenoxane_Pre1997.txt
OTN Cytosan.txt OTN Cytosan_Pre1997.txt
OTN Etopophos.txt OTN Etopophos_Pre1997.txt
OTN Paraplatin.txt OTN Paraplatin_Pre1997.txt
OTN Rubex.txt OTN Rubex_Pre1997.txt
OTN Taxol.txt OTN Taxol_Pre1997.txt
OTN Vepesid.txt OTN Vepesid_Pre1997.txt

BMS chargeback data: Chargebacks_IncludingPHS.txt
Pre1997-Indirect.txt

Wholesale List Price: PricingRevised.xls
buspar_rubex.xls

Notes:

Post-generic shares are calculated from years in which a generic was available for the entire year
See Exhibit C for an explanation of the underlying price calculations and the shares shown above
Transactions to federal government customers are excluded